Moderna shares surge 177% to record high

The move is notable less for the biotech sector itself than for what it says about how violently single-name equities can reprice on a single catalyst, and how thin the line is between momentum and fundamentals when a stock reaches a record. The item gives no detail on the driver, so the durability of the move is the open question. What matters next is whether the catalyst is a one-off event or something that changes the earnings trajectory.